Cancer cost US more than $94 billion in lost earnings in 2015

pharmafile | July 4, 2019 | News story | Research and Development |  Cancer, economics, health, lost earnings, oncology, pharma 

Cancer deaths cost the US economy $94.4 billion in lifetime earnings in 2015, according to figures from the American Cancer Society.    

“The economic burden of lost earnings from premature cancer deaths in the United States appears to be significant,” the American Cancer Society said.

The study estimated that the 492,146 people who died of cancer in 2015 could have lived for a combined total of 8.7 million more years.

Advertisement

If not for cancer, these lost years could have generated billions for the US economy, with Utah losing out on $19.6 million compared $35.3 million for those in Kentucky. In general the loss was biggest in the South and smallest in the West.  

The discrepancy can be explained by the high number of smokers and low numbers of people covered by insurance in Southern states.

While 75% of those in Utah with early stage lung cancer went in for treatment, just 50% of those in Louisiana did the same.

Fewer than half of those living in the South had insurance through their employer compared to 60% of those in Utah.

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

The Gateway to Local Adoption Series

Latest content